Journal Articles
2019

An interim report of the scleroderma clinical trials consortium
working groups
M. Baron
B. Kahaleh
E. J. Bernstein
L. Chung
P. J. Clements

See next page for additional authors

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Rheumatology Commons

Recommended Citation
Baron M, Kahaleh B, Bernstein EJ, Chung L, Clements PJ, Denton C, Domsic RT, Ferdowsi N, Narain S,
Vacca A, . An interim report of the scleroderma clinical trials consortium working groups. . 2019 Jan 01;
4(1):Article 5026 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/5026. Free
full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic
Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara
Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.

Authors
M. Baron, B. Kahaleh, E. J. Bernstein, L. Chung, P. J. Clements, C. Denton, R. T. Domsic, N. Ferdowsi, S.
Narain, A. Vacca, and +12 additional authors

This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/5026

HHS Public Access
Author manuscript
Author Manuscript

J Scleroderma Relat Disord. Author manuscript; available in PMC 2019 March 21.
Published in final edited form as:
J Scleroderma Relat Disord. 2019 February ; 4(1): 17–27. doi:10.1177/2397198318783926.

An Interim Report of the Scleroderma Clinical Trials Consortium
Working Groups

Author Manuscript

Murray Baron, MD1, Bashar Kahaleh, MD2, Elana J. Bernstein, MD, MSc3, Lorinda Chung,
MD, MS4, Philip J. Clements, MD, MPH5, Christopher Denton, PhD, FRCP6, Robyn T.
Domsic, MD, MPH7, Nava Ferdowsi, MD8, Ivan Foeldvari, MD9, Tracy Frech, M.D., M.S.10,
Jessica K. Gordon, MSc, MD11, Marie Hudson, MD1, Sindhu R. Johnson, MD, PhD12, Dinesh
Khanna, M.D., M.S.13, Zsuzsannah McMahan, M.D., M.H.S.14, Peter A. Merkel, MD, MPH15,
Sonali Narain, M.B.B.S., M.P.H.16, Mandana Nikpour, MBBS, FRACP, PhD8, John D. Pauling,
MD, PhD17, Laura Ross, MBBS, FRACP8, Antonia Maria Valenzuela Vergara, MD, MS4, and
Alessandra Vacca, M.D.18
1Division
2Faculty

of Rheumatology, Jewish General Hospital, Montreal, Canada,

of Rheumatology, University of Toledo Medical Center, Toledo, OH, USA,

3Columbia

University College of Physicians and Surgeons, New York, New York,

4Department

of Immunology and Rheumatology, Stanford University School of Medicine, Palo
Alto, CA, USA,

5Ronald

Author Manuscript

Reagan UCLA Medical Center, Los Angeles, CA, USA; University College London,
London, United Kingdom,
6Insitute

of Immunity and Transplantation, University College London, London, United Kingdom,

7Arthritis

and Autoimmunity Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA,

8Division

of Rheumatology, St. Vincent’s Hospital, Melbourne, Australia,

9Hamburg

Centre for Pediatric Rheumatology, Hamburg, Germany,

10Department

of Rheumatology, University of Utah, UT, USA,

11Department

of Rheumatology, Hospital for Special Surgery, New York, NY, USA,

12Department

of Rheumatology, Toronto Western Hospital, Toronto, Canada,

13Division

of Rheumatology, University of Michigan, MI, USA,

Author Manuscript

14Rheumatology

Department, Johns Hopkins Hospital, M.D., USA,

15Department

of Medicine, University of Pennsylvania, PA, USA,

16Department

of Rheumatology, Hosfra Northwell School of Medicine,

17Department

of Rheumatology, Royal National Hospital for Rheumatic Diseases University of

Bath,

Corresponding author: Murray Baron, MD, Chief Division of Rheumatology. Jewish General Hospital, 3755 Cote St Catherine Rd,
A-725, Montreal, QC, H3T 1E2, Tel: 514-340-8231 Fax: 514-340-7906 mbaron@rhu.jgh.mcgill.ca.

Baron et al.

Page 2

18Rheumatology

Unit, University Hospital of Cagliari.

Author Manuscript

Abstract
The Scleroderma Clinical Trials Consortium (SCTC) represents many of the clinical researchers in
the world who are interested in improving the efficiency of clinical trials in Systemic Sclerosis
(SSc). The SCTC has established 11 working groups (WGs) to develop and validate better ways of
measuring and recording multiple aspects of this heterogeneous disease. These include groups
working on arthritis, disease damage, disease activity, cardiac disease, juvenile SSc, the
gastrointestinal tract, vascular component, calcinosis, scleroderma renal crisis, interstitial lung
disease, and skin measurement. Members of the SCTC may join any one or more of these groups.
Some of the WGs have only recently started their work, some are nearing completion of their
mandated tasks and others are in the midst of their projects.

Author Manuscript

All these projects, which are described in this paper, will help to improve clinical trials and
observational studies by improving or developing better, more sensitive ways of measuring various
aspects of the disease. As Lord Kelvin stated, “To measure is to know. If you cannot measure it
you cannot improve it.” The SCTC is dedicated to improving the lives of patients with SSc and it
is our hope that the contributions of the WGs will be one important step in this process.

Author Manuscript

The Scleroderma Clinical Trials Consortium(SCTC) represents the majority of researchers
and clinicians in the world who have particular interest and expertise in the care of, and
research in, systemic sclerosis (SSc, scleroderma). The mission of the SCTC is to advance
knowledge about the treatment of SSc primarily by promoting efficient design, conduct, and
reporting of results of clinical trials and observational studies. To this end the SCTC has
assembled an assortment ofworking groups (WGs) that are tasked to investigate various
aspects of scleroderma. In general, they are focused on better ways to measure various
aspects of the disease. These measures are essential for the conduct of good clinical trials
and observational studies.
In this report we will briefly summarize the projects of these WGs. The Table shows a
summary of the WGs and the contact for the principal investigators should the reader wish to
join a group.

1.

Arthritis WG. PI: authors JG, PC and SJ.

Author Manuscript

Musculoskeletal disease in SSc leads to disability and poor quality of life(1).
Musculoskeletal disease including arthritis and tendinopathy has been observed in24% to
97% of SSc patients at some time during the course of their illness(2). Synovitis, joint
contracture, and tendon friction rubs (TFRs) are associated with early disease, disease
severity, and with higher degrees of systemic inflammation(3, 4). Joint synovitis and TFRs
were shown to be independent predictive factors for disease progression in early SSc(5).
However, these manifestations are frequently overlooked in the context of clinical trials in
part because outcome measures have not been developed for Musculoskeletal symptoms (6).
This WG was formed in order to identify a core set of preliminary items considered as
important for the study of arthritis and arthropathy in SSc.
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In order to explore the opinions of scleroderma experts regarding utility of potential outcome
measures in SSc joint disease, we conducted a two-part Delphi exercise. We utilized webbased technologies to conduct the Delphi exercise. In 2 rounds of electronic voting, experts
from the SCTC email list were asked to rate various outcome measures with respect to their
use in future clinical trials focused on arthritis in SSc. Individuals ranked each item 1–9 on a
Likert scale with the intent to disregard any items with a mean score <3, keep items with a
mean score >7 and reconsider items rated between 3 and 7.

Author Manuscript

Fifty physicians from SCTC centers participated. They were provided with a list of 29 items
to consider initially, which was increased to 31 items during the second round. Consensus
was achieved after 2 rounds of voting. The experts agreed that the following 7 items should
be useful in an arthritis-focused SSc trial: 28 joint tenderness count, 28 joint swelling count,
assessment of TFRs, assessment of contractures of small and large joints, C-reactive protein,
Scleroderma Health Assessment Questionnaire-Disability Index, patient global visual
analogue scale. No items on the list were ranked in the disregard category.
The two round Delphi exercise identified 7 items considered by experts as well-suited for the
study of arthritis in SSc, but there was considerable ambivalence regarding the performance
of these potential outcome measures for SSc arthritis. The validation of these outcome
measures for use in interventional studies of SSc-arthritis is called for and is the focus of this
group moving forward.

2.

Disease Damage WG. PI: authors NF, MB, MN

Author Manuscript

The Scleroderma (SSc) Clinical Trials Consortium Damage Index (SCTC-DI) Working
Group was assembled in November 2013. The mandate of this working group of 24
members, including 22 rheumatologists and 2 dermatologists from North and South
America, Australia and Europe, was to develop the first disease Damage Index in SSc, an
instrument to quantify organ damage in this disease. The SCTC-DI Working Group was
aided by an Advisory Group of 7 non-rheumatology experts from the disciplines of
cardiology, respiratory medicine, gastroenterology and nephrology, together with 3 patient
partners.

Author Manuscript

The first task of the SCTC-DI Working Group was to achieve a consensus definition of
‘damage’ in SSc. This was achieved through a two-round survey of the Working Group
members, and consultation with the Advisory Group and patient partners. Items for potential
inclusion were generated through a systematic review of the literature (7)and items were
added based on suggestions of the WG members, the Advisory Group and the patient
partners. The final list of items was then presented in survey form to the members of the
SCTC, who were asked to rate the appropriateness of each item, in terms of importance and
feasibility, for inclusion in the SCTC-DI. In this manner, over 80 items were reduced to just
over 50. Further item reduction and ‘weighting’ was achieved through regression methods
relating each item with the endpoints of quality of life (‘morbidity’) measured using SF-36
and mortality, in the Australian Scleroderma Cohort Study data set of over 1500 patients
followed prospectively over a median follow-up of 4 years. External validation of the SCTCDI in the Canadian Scleroderma Research Group cohort has shown excellent performance

J Scleroderma Relat Disord. Author manuscript; available in PMC 2019 March 21.

Baron et al.

Page 4

Author Manuscript

characteristics against similar morbidity and mortality endpoints, and steady accrual of
damage over time, indicating responsiveness in an observational cohort setting. A
manuscript reporting the derivation and initial validation of the SCTC-DI is currently being
prepared for submission for peer review publication.
Future projects include prospective validation of the SCTC-DI in the International Systemic
Sclerosis Inception Cohort (INSYNC) of patients followed from disease onset, and
assessment of discriminant validity in interventional studies. Future applications of the
newly derived SCTC-DI include use as an outcome measure and enrichment tool for patient
selection in clinical trials, a tool to describe the course of the disease in observational
studies, and an instrument to quantify disease burden for epidemiological studies and policy
making.

Author Manuscript

As activity and damage lie on the same continuum, the development of the SCTC-DI has
laid the foundations for the development of an Activity Index using similar methodology.

3.

Disease Activity WG. PI: authors LR, MB, MN
The EUSTAR Activity Index (EScSG-AI) (8, 9) is the only previously published SSc
activity index. The EScSG-AI was recently revised in 2017(9), however, it has not yet been
fully validated. This remains an issue of great clinical significance as SSc continues to have
the highest case-based mortality of any autoimmune connective tissue disease (10). Thus,
accurate identification of high disease activity is of utmost importance in order to apply
targeted therapy to lower the risk of organ damage.

Author Manuscript

The SCTC Activity WG is a collaboration of international SSc experts working towards
generating a weighted, multi-system index to identify and measure SSc disease activity.
Similarly to the Damage Index WG, a multidisciplinary advisory panel of non-rheumatology
experts and patient partners have been assembled to provide advice and recommendations
regarding aspects of disease activity relevant to their specific fields of expertise. Whilst
conceptually, activity and damage are two distinct concepts, attribution of features of SSc to
either disease activity or damage is not always straightforward. The complex, multi-system
nature of SSc, its progressive rather than relapsing and remitting disease course, the late
clinical presentation of many disease features and a lack of biomarkers all contribute to the
significant difficulty researchers and clinicians have in defining and measuring SSc disease
activity.

Author Manuscript

As a first step in developing an activity index, the SCTC Activity WGdevelopeda consensus,
conceptual definition of disease activity in SSc. This conceptual definition of disease activity
will then form the central construct of the planned SCTC Activity Index (SCTC-AI). Careful
attention will be paid to the Outcome Measures in Rheumatology (OMERACT) filters of
truth, discrimination and feasibility(11) in the development of the SCTC-AI.
Using a similar methodology to that employed in the development of SCTC-DI,
development of items for the SCTC-AI will draw upon the expertise of the SCTC WG and
systemic review of the literature. Reduction and weighting of items will be performed using
data from the Australian Scleroderma Cohort Study (ASCS). Data from the Canadian

J Scleroderma Relat Disord. Author manuscript; available in PMC 2019 March 21.

Baron et al.

Page 5

Author Manuscript

Scleroderma Research Group (CSRG) cohort study will be used for retrospective validation
in an external cohort and prospective validation studies will be performed using data from
the INSYNC study. In all of these validation studies, the endpoints of interest will be healthrelated quality of life (HRQoL), physical function, organ damage (measured by the SCTCDI), and mortality.By ensuring that the SCTC-AI has face value, measures what is intended,
and readily discriminates between high and low disease activity states, it is hoped that the
SCTC-AI will overcome the criticisms faced by other outcome measures and be the first
fully validated SSc disease activity outcome measure.

4.

Cardiac WGPI: authors AV,LR, MB, MN

Author Manuscript

The aim of the SCTC Cardiac WG is to develop a definition of primary cardiac involvement
in SSc for use in clinical trials and in observational studies. Currently, there is no consensus
definition of SSc-cardiomyopathy and this is reflected in the highly variable reporting of SSc
heart involvement (SCH) and its prevalence. SCH is highly heterogeneous and includes
variable involvement of many cardiac structures including the myocardium, conduction
system, pericardium and cardiac valves. Early definitions of SCH have included congestive
cardiac failure, arrhythmias requiring therapy and symptomatic Pericarditis (12, 13). The
prevalence of SCD using these criteria was 15% in a cohort of patients with diffuse SSc and
these patients, particularly those with symptomatic cardiomyopathy, had poor clinical
outcomes(13).

Author Manuscript

Autopsy studies have demonstrated SCH in up to 80% of patients and whilst no individual
finding is pathognomonic for SCH, features of microvascular damage, myocardial fibrosis
and inflammation are considered characteristic of SSc heart disease (14, 15). A definition of
SCH would ideally incorporate the underlying pathophysiological processes, however
routine investigations such as electrocardiography, chest radiograph and transthoracic
echocardiography are known to have a low sensitivity for the detection of SCH prior to the
onset of clinically overt disease(16). There is emerging evidence of a role for more sensitive
diagnostic techniques such as tissue Doppler echocardiography(TDE), and cardiac magnetic
resonance imaging (CMR)(17), and for biomarkers such as N-terminal pro B-type natriuretic
peptide(18), and high sensitivity cardiac troponin(19, 20). However, the clinical significance
of abnormalities detected by newer investigation modalities remains uncertain.

Author Manuscript

There are a significant number of other unresolved issues when considering SCH; namely,
the effect of co-morbidities on the myocardium and attribution of cardiac disease to SSc, as
well as appropriate screening algorithms and optimal treatment and follow-up of patients
diagnosed with SCD. The lack of an accepted, standardised definition of SCH impedes
progress in all of these areas.
The SCTC CardiacWG has recruited cardiologists from Europe, North America and
Australia to assist in the development of a preliminary working definition of SCH. The WG
will be asked to consider the scope of cardiac disease that should be included in a definition
of SCH. Questions to be considered are should the definition of SCH be restricted to SSc
affecting the myocardium only, and should SCH considered present only if patients are
symptomatic? A scoping literature review of previously published definitions of SCH has
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been performed. With these results and by drawing upon the expertise within the group, the
Cardiac WG is aiming to develop a consensus, expert-opinion definition of SCH. In parallel,
the Cardiac WG is also developing a research agenda to pursue the role of novel
echocardiography techniques and CMR in the diagnosis of SCH and establishing cohort
studies to better describe the natural history of SSc cardiac disease. There are now validated
methods to non-invasively assess cardiac fibrosis with CMR, avoiding the need for
endomyocardial biopsy(21). This offers SSc-researchers an opportunity to evaluate larger
numbers of patients to precisely quantify the burden of myocardial fibrosis in SSc and
potentially develop a feasible clinical method to diagnose SHI, prior to the onset of severe
heart failure.

5.

Juvenile scleroderma WG. PI: Author IF

Author Manuscript

Juvenile systemic scleroderma (jSSc) is a much rarer than the adult form. The estimated
prevalence is 3 per 1 million child based on the Administrative Claims Data from the United
States (Beukelman and Foeldvari et al, in press JSRD). The only published cross sectional
study regarding incidence from the United Kingdom and Ireland that relied upon surveys of
specialist, estimated a yearly incidence of 0.27 [0.10–0.50] per 1 million child(22).
Currently there is a proposed severity index published for jSSc(23), which is a modification
of the Medsger severity index, however it is not yet validated. In the evaluation of the
juvenile severity index (23) in the juvenile scleroderma inception cohort
population(www.juvenile-scleroderma.com), the index appears to be unresponsive to
improvement but it did correlate with the Modified Rodnan skin score( unpublished data
Foeldvari et al).

Author Manuscript

Several outcome measures exist for adult SSc patients including the Valentini activity
index(9), the CRISS response index(24), the Medsger severity index(25) and the proposed
SCTC damage index. Unfortunately, none is validated in the pediatric population.
As new therapeutics are investigated in adults with SSc, pediatric studies will be planned. It
is crucial to define response index, activity index and remission in the pediatric population.
A further important step for jSSc treatment studies is the decision of European Medical
Agency on extrapolation of the data(26, 27), to license treatment faster for pediatric orphan
diseases.
The aim of the WG is to develop, adopt and validate outcome measures for jSSc.

Author Manuscript

Three workshops took placeduring the annual meeting of the “Hamburg Symposium on
Juvenile Scleroderma- Update on New Developments”, (www.juvenile-scleroderma.com)
that were organised by Ivan Foeldvari, to develop a pediatric “CRIS” and other pediatric
jSSc specific outcome measures. In the last workshop a preliminary pediatric CRIS was
proposed (manuscript in preparation).We are also in the process of validating the proposed
pediatric and adult parameters in the juvenile scleroderma inception cohort (www.juvenilescleroderma.com),and in the Childhood Arthritis and Rheumatology Research Alliance
(CARRA) cohort.
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We hope that we will have a validated instrument, regarding definition of activity, response,
remission and damage, which can be applied in Phase II and III studies testing new therapy
for jSSc. The indices will help clinicians in the day to day practice too.

6.

Gastrointestinal Tract WG PI: authors TF, ZM, DK

Author Manuscript

Gastrointestinal (GI) tract symptoms are very common in SSc. The etiology of these
symptoms is thought to be similar to other organ system pathophysiology with interrelated
progressive immune dysregulation, vasculopathy, and fibrosis occurring throughout the GI
tract. The study of GI symptoms in SSc must capture not only the severity of involvement,
but also response of those symptoms to intervention. The ideal patient reported outcome
measure should be able to provide information to guide the treating physician and inform
clinical trial design while also minimizing the burden on the patient. The SCTC-GI-WG
acknowledges the unmet need of a longitudinal assessment of response to therapy in SScassociated GI tract involvement (28). Patient reported outcomes measurement system
(PROMIS) questionnaires were developed to characterize GI symptoms from the esophagus
to the anorectum. The GI-WG focused on assessing psychometric properties of various GIspecific patient reported outcome measures in 5 conditions—gastroesophageal reflux
disease, gastroparesis, small intestinal bowel bacterial overgrowth, constipation, and fecal
incontinence. Our WG comprises six international scleroderma centers from the United
States and one each from Italy, Belgium and Australia. All data is entered at baseline and in
follow-up into a database which was developed and is maintained at the University of
Michigan.

Author Manuscript

We recently assessed the reliability, validity, and sensitivity to change of 3 PROs- the NIH
PROMIS-GI Symptoms scale, the Scleroderma Clinical Trials Consortium University of
California Los Angeles Gastrointestinal Tract (SCTC UCLA GIT 2.0), and the Quality of
life in Reflux and Dyspepsia (29), in 116 participants with SSc and active GERD with an
average age of 53.8 years and mean disease duration of 12.0 years. The UCLA GIT 2.0
Reflux scale and PROMIS Reflux scale had a significant correlation at baseline (0.61,
p=<0.0001), and both instruments correlated with the QOLRAD domains (−0.56 to −0.71).
Both UCLA GIT 2.0 and PROMIS Reflux scales were sensitive to change over time in
patients who improved over a period of 4 weeks after an intervention.

Author Manuscript

The SCTC GI WG is now actively recruiting patients for the other SSc GI symptom
domains. The next anticipated step is to better clarify the etiology of bloating and distention
in an international cohort. Patient reported outcomes instruments that are applied to this
cohort after a single intervention for GI symptoms can help inform clinical practice and trial
design.

7.

Vascular WG. PI: authors JP, RD
The aims of the SCTC Vascular WG (VWG) are to develop/improve outcome measures for
SSc vascular manifestations. Challenges in establishing treatment efficacy in clinical trials of
Raynaud’s phenomenon (RP) led the nascent SCTC-VWG to appraise existing methods for
assessing SSc-RP. The Raynaud’s Condition Score (RCS) is the preferred outcome measure
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for SSc-RP and is included in the provisional core set of outcome measures for SSc clinical
trials (30). The RCS diary collects information on the frequency, duration and severity/
impact of RP in SSc(31). It is a clinician-derived patient-reported outcome [PRO]
instrument, but there was no patient involvement in its development(32). Therefore, studies
have identified poor agreement between the RCS diary and objective methods for assessing
digital microvascular function (33, 34). Concerns have also been raised about the magnitude
of the placebo effect in clinical trials incorporating the RCS diary (35).
The SCTC-VWG undertook a survey of the attitudes of SSc experts towards the RCS diary.
The SURPASS (Subjective Raynaud’s phenomenon Assessment in Systemic Sclerosis)
survey identified several concerns about the 2-week RCS diary including the respondent
burden and an inability to control for factors that might influence the reporting of RP
symptoms (36).

Author Manuscript

To this end, SCTC funding was obtained to devise a conceptual framework for a novel
patient-derived PRO instrument for SSc-RP, supported by a steering committee comprising
SSc patients, SSc experts and qualitative researchers.

Author Manuscript

Preliminary work included a comprehensive literature review that has highlighted the
significant burden associated with SSc-RP not captured by the RCS diary(37). A multicenter
qualitative research study designed to examine the patient experience of SSc-RP from a
broad ethnic, geographic and cultural population of SSc patients has supported and
expanded these findings (38). A purposive sampling framework ensured the enrollment of a
diverse but representative group of 40 patients with SSc. We identified important
experiences of SSc-RP not captured by the RCS diary including emotional distress, body
image dissatisfaction, impaired social participation and relevant physical symptoms such as
feeling “cold” (38). Our findings have challenged the prevailing paradigm of SSc-RP being
only an episodic phenomenon with physical symptoms such as pain, numbness and loss of
hand function reported in a more sustained manner and reflecting persistent digital ischemia
in SSc(38). The considerable efforts taken by patients to avoid or ameliorate SSc-RP attacks
were a major theme of the focus groups (38). In parallel work, SSc patients attending UK
and US sites undertook2-week RCS diary collection and then completed a qualitative survey
examining patient attitudes towards the instrument (39). The findings confirmed our
suspicions that the RCS diary underestimates the true burden of RP symptoms and provides
insight as to why the RCS diary has not performed as well as hoped in clinical trials whose
primary endpoint is the frequency of SSc-RP attacks (39–41).

Author Manuscript

Work within the SCTC-VWG is currently underway on item-generation for a novel PRO
instrument for SSc-RP, grounded in the patient experience of SSc-RP identified in our
preliminary work.

8.

Calcinosis WG PI: author LC, AV
Calcinosis cutis, the deposition of calcium in the skin and subcutaneous tissues, is a
common and potentially debilitating issue affecting approximately one quarter of SSc
patients(42, 43). To date, there are no effective therapies for this complication and there is a
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lack of validated outcome measures to use in clinical trials(44). The SCTC Calcinosis-WG is
an international collaborative effort to create new trial outcome measures and better
understand the course and consequences of this complication.
Studies have shown an association between calcinosis and vascular manifestations of SSc
including digital ulcers (DUs, (45–47) and acro-osteolysis(48), suggesting a role for
ischemia in the pathogenesis of calcinosis. In addition, microtrauma has been implicated in
the pathogenesis of calcinosis, and a prior single-center study found that the thumbs were
most commonly affected, supporting this hypothesis(49).

Author Manuscript

Our group performed a retrospective analysis involving 5218 patients with SSc from 9
cohorts within the US, Australia, Canada, United Kingdom, Italy, and Mexico. In
multivariate analysis, the strongest associations with calcinosis were DUs and
osteoporosis(43).
Our group has developed a novel radiographic scoring system to assess the severity of
calcinosis affecting the hands that accounts for area coverage, density, and anatomic
location. This scoring system was found to have excellent intra- and inter-rater reliability
with intra-class correlation coefficients (ICC) of .93 (.89-.97) and .89 (.86-.92),
respectively(50). Similarly, we have developed a patient reported outcome measure specific
to calcinosis (the Mawdsley Calcinosis Questionnaire, (51).
We have established a prospective multi-center cohort of SSc patients with and without
calcinosis to better define the natural history, confirm clinical associations, and further
validate these novel outcome measures. Data is being collected from 15 centers, 8 of whom
are also participating in a sub-study to validate the radiographic scoring system.

Author Manuscript

We are collecting patient questionnaires at baseline and 1-year, including the Cochin Hand
Functional Scale, Scleroderma Health Assessment Questionnaire, patient global assessment
of calcinosis using a visual analog scale (VAS, 0–10), and the novel Mawdsley calcinosis
questionnaire. In addition, physician global assessment of calcinosis VAS is being collected
at baseline and 1-year, and a 5-point Likert scale at the 1-year visit for both patients and
physicians to rate change in calcinosis.

Author Manuscript

Information on 556 patients has been entered into the central database from which 134 have
completed 1-year follow-up and 60 are participating in the radiographic sub-study.
Enrollment is expected to be completed in March 2018. We plan to compare patients with
and without calcinosis with respect to demographic characteristics, clinical features, and
autoantibodies, and to specifically assess the association between calcinosis and DU or
osteoporosis, adjusting for other relevant variables. We will also determine the mean rate of
change of calcinosis for the subset of patients who have baseline and 1-year hand
radiographs(50). We hope to identify a subgroup of patients with rapid calcinosis
progression and to determine risk factors for this severe phenotype.
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Scleroderma Renal Crisis WG. PI: authors MH,CD
Scleroderma Renal Crisis (SRC) is characterized by acute, malignant hypertension and renal
dysfunction. It is a rare complication of SSc, affecting approximately 5% of subjects. The
clinical spectrum of SRC is broad, ranging from new onset accelerated arterial hypertension
and rapidly progressive oliguric renal failure, to more modest elevations in blood pressure
and renal dysfunction, and at times normotensive presentations. To date, two sets of criteria
for SRC have been proposed and partially validated(52, 53). We wish to build on these
preliminary efforts to develop classification criteria for SRC and improve systematic
research in this condition.

Author Manuscript
Author Manuscript

The SCTC SRC-WG that consistsof international experts from rheumatology, nephrology
and pathology was created in November 2015. A scoping review to generate evidence-based
items to define SRC was performed during 2016, presented to the SCTC SRC WG in
Washington, DC, in November 2016, and published in February 2017 (54). We identified
415 papers that met inclusion criteria. Forty original definitions of SRC were identified from
36 studies, 9 reviews and 2 editorials. There was significant heterogeneity in definitions. In
May-October 2017, we conducted a 3-round online Delphi exercise to develop initial
consensus on a core set of items to define SRC. A survey using the items identified by the
scoping review was developed. An international, multidisciplinary panel of experts from the
SCTC, European Scleroderma Trials and Research Group (EUSTAR), the Canadian
Scleroderma Research Group (CSRG), and the Australian Scleroderma Interest Group
(ASIG) were invited to participate. A Delphi exercise was performed in 3 rounds. In Round
1, participants were asked to identify omissions and clarify ambiguities. The survey was
modified accordingly. In Round 2, participants were asked to rate the scientific validity and
feasibility of the items using Likert-type scales ranging from 1–9 (1= very invalid/
unfeasible, 9 = very valid/feasible), and to provide comments. In Round 3, participants
reviewed the results and were asked to provide final ratings. Consensus was defined as items
rated highly valid and feasible (both median scores ≥7) in Round 3, and for which there was
no disagreement, calculated using the RAND/UCLA Appropriateness Method formula(55).
Ninety-nine experts from 17 countries participated in the Delphi exercise. Of the 31 items in
the survey, consensus was achieved on items pertaining to hypertension, kidney dysfunction,
proteinuria and hemolysis. Consensus was not achieved on items pertaining to hematuria,
thrombocytopenia, encephalopathy, retinopathy, hyper-reninemia, cardiac dysfunction and
histopathology.

Author Manuscript

In November 2017, a nominal group discussion was held in San Diego, CA, to achieve final
consensus on the core set. Final consensus was achieved on items for blood pressure, acute
kidney injury, microangiopathic hemolytic anemia and thrombocytopenia, target organ
dysfunction (cardiac dysfunction, retinopathy and encephalopathy) and histopathology.
Two additional components of this research project are now in the planning phases. First,
modeled on the International Scleroderma Renal Crisis Survey (ISRCS,(53), ISRCS II will
be developed and launched to collect a new inception SRC cohort to validate the consensus
criteria using data-driven methods. Second, a forced choice study using multi-criteria
decision analysis methods(56), will be performed with the experts who participated in the
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nominal group discussion to assign weights to the items in the criteria. Among other things,
this may allow sub-classifying SRC into hypertensive and normotensive subsets.
This project will generate the first validated classification criteria for SRC. These criteria are
expected to become the international standard and will be used in future randomized trials
and epidemiologic research of SSc.

10.

Skin WG. PI: authors JG, PM, DK

Author Manuscript

Skin involvement in SSc is the most pathognomonic feature and an important manifestation
of disease and a marker of severity (57, 58) , which makes its assessment a key outcome in
clinical research in SSc. Skin involvement is routinely quantified using the 17-site modified
Rodnan skin score (mRSS) which assesses global dermal thickness through clinical
palpation of 17 body areas scored using a 4-point ordinal scale. The mRSS has high
feasibility, validity (face, content, construct, and criterion), reliability, and sensitivity to
change(59). The goal of this SCTC WG is to explore ways to improve the assessment of skin
disease in SSc.
Although mRSS has excellent intra-rater and inter-rater reliabilities(60, 61) individual
examiners approach the mRSS in different ways in clinical practice. Commonly-used
techniques for a given area of the body include choosing a maximum score, a representative
area, or a global average. If the examiner is consistent with his or her approach to scoring
each time, the mRSS will be valid in the course of a trial. However, it is possible that
maximizing the score may lead to decreased sensitivity to change of the mRSS. This WG
plans to explore this controversy.

Author Manuscript

It has been observed that certain areas of the body are more sensitive to change than others.
Kaldas, et al showed that hands, forearms and chest were more sensitive to change compared
with other body sites in two human recombinant relaxin and oral bovine collagen clinical
trials(62). Fernandez, et al showed a lower propensity for change of the fingers over the
course of 3 single-center trials(63). These observations lead to the question of whether
decreasing the number of body sites by exclusion of relatively static areas would further
increase the sensitivity to change over time or reliability of the total MRSS. Our goal is to
look at these questions in the context of studies that show more significant change as well as
over a longer duration.

Author Manuscript

Further goals of this group will include investigation of complementary methods of
assessing skin disease that can studied as secondary outcomes in clinical trials. Ideas include
percentage change mRSS, percentage of body involvement, and possibly use of skin
biopsies, ultrasound, or durometry depending on investigator interest. Importantly, the WG
seeks to align its agenda with the SCTC’s efforts to standardize skin scoring and advance the
science of clinical trials in SSc.

11.

Lung Disease WG. PI: authors EB, SN
Interstitial lung disease (ILD) is the primary cause of death in SSc(64). Although there have
been many trials for the treatment of SSc-ILD, inclusion criteria have varied widely across
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studies and it remains unclear which patients to enroll to maximize the likelihood of
achieving the predefined primary endpoints.
The aim of this WG is to harmonize inclusion criteria for clinical trials of SSc-ILD. We have
reviewed the inclusion and exclusion criteria for 9 completed and ongoing SSc-ILD clinical
trials since the year 2000(65–75).While age at time of enrollment and SSc classification
criteria were fairly consistent across studies, there was considerable variability with respect
to disease duration, pulmonary function test (PFT) cut points, high resolution computed
tomography of the chest (HRCT) characteristics, and acceptable background therapies.
While some inclusion and exclusion criteria will need to be specific to the particular drug
being investigated, developing “optimal inclusion criteria” may ultimately help improve
outcomes of SSc-ILD clinical trials.

Author Manuscript

At the inaugural meeting of the SCTC Lung Disease WG in 2017, an initial research agenda
was defined as determining how best to define progression of SSc-ILD and whether SScILD progresses in patients who have had SSc for ≥ 7 years. We will perform a nominal
group technique and Delphi exercise to develop consensus among SSc experts. We will then
apply the core set of inclusion and exclusion criteria to clinical trial data and observational
cohort data to validate their performance. Using well-established SSc cohorts throughout the
world and applying the definition of progressive SSc-ILD that we develop, we will
subsequently determine whether patients with ≥ 7 years of disease have progression of their
ILD.

Conclusions
Author Manuscript

The SCTC WGs are one aspect of an organization tasked with improving the efficacy of
clinical trials. This interim report summarizes the work of the SCTC WGs to date.
The groupshave benefited greatly from the input and effort of the SCTC members who have
attended meetings over many years. Members generously contributed their time, effort and
wide-ranging expertise on subjects as diverse as the disease that we are studying. Members’
involvement has ensured that the WGs reports will reflect a wide range of perspectives and
skills. Leaders of the groups are grateful for the tireless input of all those who have been
involved in these many exercises.
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Retrospective analysis involving
5218 patients with SSc from 9
cohorts; developed a novel

Completed survey of the
attitudes of SSc experts towards
the RCS diary; comprehensive
literature review; multicenter
qualitative research study to
examine the patient experience
of SSc-RP

Assessemnts of the reliability,
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course and
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forced choice study to
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patients with rapid
calcinosis progression
and to determine risk
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